Cerebricon Announces Updates To Product Portfolio
01 May 2007
Cerebricon is pleased to announce the following additions to its portfolio of in vivo models:
- (EAE) Model for multiple sclerosis
- R6/2 Transgenic model for Huntington's disease
- In vitro model for 6-OHDA induced dopaminergic cell death
- Celebral Blood Flow (CBF) analysis using MRI in CNS study
In addition, Cerebricon announces the commencement of its last in-house quality assessment of the Tg2576 Transgenic Model for the study of Alzheimer's disease, as well as the release of the acute model of Aß-induced cognitive dysfunction.
Cerebricon welcomes the opportunity to present its in-house validation data on these, and any other CNS disease models, to its present and prospective clients.
